Thanks @Quitman for that post.
With Relyvrio out of the way. Basically leaves ourselves v Riluzole and Radicava. Riluzole increases median survival by up to 19 months .
Radicava costs $145 K PY . Short half live. 6 months median survival . Folks, that is our opposition now. PAA are now in a unique situation of saying to BP this is what we want in $. That's my read.
Kpax
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
16.5¢ |
Change
-0.005(2.94%) |
Mkt cap ! $81.23M | |||
| Open | High | Low | Value | Volume |
| 16.5¢ | 17.0¢ | 16.0¢ | $57.64K | 349.3K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 7 | 86989 | 16.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 16.5¢ | 2606 | 1 |
View Market Depth
| Last trade - 14.17pm 15/07/2025 (20 minute delay) ? |
| NUZ (ASX) Chart |